Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 1 Issue 2, April 1983

Editorial

Top of page ⤴

News

Top of page ⤴

Feature

  • Liposomes were once touted as membranous “magic bullets” that would be modern, all-purpose carriers for drugs, enzymes, and genetic material. While this overoptimistic appraisal led to disappointment, researchers have found new applications for liposome technology and new ways to engineer liposomes to perform specific functions. These applications have attracted investment in several liposome-based companies and in research programs at multinational pharmaceutical houses. A number of liposome-based diagnostic, therapeutic, and veterinary products will soon face the test of the marketplace. Meanwhile, promising research results indicate that highly focused R&D programs could lead to a new generation of immune stimulants and anti-cancer agents based upon the liposome's ability to stimulate cellular processes.

    • Tazewell Wilson
    • Lynn Cave
    Feature
  • Commercialization of monoclonal antibodies may be the biotechnology success story of the 1980s. While most products of genetic engineering are still characterized as having potential or hypothetical commercial applications, there are at least 30 monoclonal antibody-based products on the market now. Hybritech, a California biotechnology firm, leads the field in production and marketing of new applications for monoclonal antibodies.

    • Lawrence Prescott
    Feature
Top of page ⤴

Technology Report

Top of page ⤴

Commentary

Top of page ⤴

Review Article

Top of page ⤴

Research Paper

Top of page ⤴

Publications

Top of page ⤴

Announcements

Top of page ⤴

New Products

Top of page ⤴

Bio/Text

Top of page ⤴

Patents

Top of page ⤴

Final Word

Top of page ⤴

Search

Quick links